对冠状动脉植入现有药物洗脱支架后内皮覆盖延迟预测因素的病理学评估:急性和慢性冠状动脉综合征病变的影响。

IF 3.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS American heart journal Pub Date : 2024-08-08 DOI:10.1016/j.ahj.2024.08.003
Kazuki Aihara MD , Sho Torii MD, PhD , Norihito Nakamura MD, PhD , Hideki Hozumi MD , Manabu Shiozaki MD , Yu Sato MD , Marie Yoshikawa MD , Norihiko Kamioka MD , Takeshi Ijichi MD, PhD , Makoto Natsumeda MD , Yohei Ohno MD, PhD , Takahide Kodama MD, PhD , Tomoya Onodera MD, PhD , Yoshiaki Mibiki MD, PhD , Hayato Ohtani MD, PhD , Ryosuke Kametani MD, PhD , Ayako Yoshikawa RN , Naoya Nakamura MD, PhD , Yuji Ikari MD, PhD , Gaku Nakazawa MD, PhD
{"title":"对冠状动脉植入现有药物洗脱支架后内皮覆盖延迟预测因素的病理学评估:急性和慢性冠状动脉综合征病变的影响。","authors":"Kazuki Aihara MD ,&nbsp;Sho Torii MD, PhD ,&nbsp;Norihito Nakamura MD, PhD ,&nbsp;Hideki Hozumi MD ,&nbsp;Manabu Shiozaki MD ,&nbsp;Yu Sato MD ,&nbsp;Marie Yoshikawa MD ,&nbsp;Norihiko Kamioka MD ,&nbsp;Takeshi Ijichi MD, PhD ,&nbsp;Makoto Natsumeda MD ,&nbsp;Yohei Ohno MD, PhD ,&nbsp;Takahide Kodama MD, PhD ,&nbsp;Tomoya Onodera MD, PhD ,&nbsp;Yoshiaki Mibiki MD, PhD ,&nbsp;Hayato Ohtani MD, PhD ,&nbsp;Ryosuke Kametani MD, PhD ,&nbsp;Ayako Yoshikawa RN ,&nbsp;Naoya Nakamura MD, PhD ,&nbsp;Yuji Ikari MD, PhD ,&nbsp;Gaku Nakazawa MD, PhD","doi":"10.1016/j.ahj.2024.08.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The optimal duration of dual antiplatelet therapy after currently available drug-eluting stent (DES) implantation to prevent stent thrombosis (ST) remains controversial. Delayed healing is frequently identified as a leading cause of ST in the early phase. However, a thorough pathological investigation into strut coverage after currently available DES implantation is lacking—a gap addressed in the current study.</p></div><div><h3>Methods</h3><p>From our autopsy registry of 199 stented lesions, 4,713 struts from 66 currently available DES-stented lesions with an implant duration ≤370 days were histologically evaluated. Endothelial coverage was defined as the presence of luminal endothelial cells overlying struts and an underlying smooth muscle cell layer. The stented lesions were classified into acute coronary syndrome (ACS) (n = 40) and chronic coronary syndrome (CCS) (n = 26) groups and were compared. Endothelial coverage predictors were identified through logistic analysis.</p></div><div><h3>Results</h3><p>Although ACS and CCS lesions presented comparable clinical characteristics, including age, sex, and cause of death, the latter exhibited a significantly higher prevalence of chronic kidney disease and hemodialysis than the former (33.3% vs. 65.2%; <em>P</em> = .02, 7.7% vs. 30.4%; <em>P</em> = .02). The poststent implant median duration was significantly shorter in ACS lesions than in CCS lesions (13 [IQR 5-26 days] vs. 40 [IQR 16-233 days]; <em>P</em> &lt; .01). The endothelial coverage percentage was 3.5% at 30 days and 27.7% at 90 days after currently available DES implantation. Multivariable logistic regression analysis implicated implant duration of ≤90 days (odds ratio [OR], 0.009; 95% confidence interval [CI], 0.006-0.012; <em>P</em> &lt; .01), superficial calcification (OR, 0.11; 95% CI, 0.07-0.17; <em>P</em> &lt; .01), ACS culprit site (OR, 0.29; 95% CI, 0.09-0.94; <em>P</em> = .039), and circumferentially durable polymer-coated DES (OR, 0.32; 95% CI, 0.24-0.41; <em>P</em> &lt; .01) as delayed endothelial coverage predictors.</p></div><div><h3>Conclusions</h3><p>Endothelial coverage was limited at 90 days after currently available DES implantation, and the ACS culprit site and circumferentially durable polymer-coated DES were identified as independent predictors of delayed endothelial coverage. Our findings suggest the importance of underlying plaque morphology and stent technology for vessel healing after such implantation.</p></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"277 ","pages":"Pages 114-124"},"PeriodicalIF":3.7000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0002870324001972/pdfft?md5=a6d96a92c2b7b068b125c59613afe3dc&pid=1-s2.0-S0002870324001972-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Pathological evaluation of predictors for delayed endothelial coverage after currently available drug-eluting stent implantation in coronary arteries: Impact of lesions with acute and chronic coronary syndromes\",\"authors\":\"Kazuki Aihara MD ,&nbsp;Sho Torii MD, PhD ,&nbsp;Norihito Nakamura MD, PhD ,&nbsp;Hideki Hozumi MD ,&nbsp;Manabu Shiozaki MD ,&nbsp;Yu Sato MD ,&nbsp;Marie Yoshikawa MD ,&nbsp;Norihiko Kamioka MD ,&nbsp;Takeshi Ijichi MD, PhD ,&nbsp;Makoto Natsumeda MD ,&nbsp;Yohei Ohno MD, PhD ,&nbsp;Takahide Kodama MD, PhD ,&nbsp;Tomoya Onodera MD, PhD ,&nbsp;Yoshiaki Mibiki MD, PhD ,&nbsp;Hayato Ohtani MD, PhD ,&nbsp;Ryosuke Kametani MD, PhD ,&nbsp;Ayako Yoshikawa RN ,&nbsp;Naoya Nakamura MD, PhD ,&nbsp;Yuji Ikari MD, PhD ,&nbsp;Gaku Nakazawa MD, PhD\",\"doi\":\"10.1016/j.ahj.2024.08.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The optimal duration of dual antiplatelet therapy after currently available drug-eluting stent (DES) implantation to prevent stent thrombosis (ST) remains controversial. Delayed healing is frequently identified as a leading cause of ST in the early phase. However, a thorough pathological investigation into strut coverage after currently available DES implantation is lacking—a gap addressed in the current study.</p></div><div><h3>Methods</h3><p>From our autopsy registry of 199 stented lesions, 4,713 struts from 66 currently available DES-stented lesions with an implant duration ≤370 days were histologically evaluated. Endothelial coverage was defined as the presence of luminal endothelial cells overlying struts and an underlying smooth muscle cell layer. The stented lesions were classified into acute coronary syndrome (ACS) (n = 40) and chronic coronary syndrome (CCS) (n = 26) groups and were compared. Endothelial coverage predictors were identified through logistic analysis.</p></div><div><h3>Results</h3><p>Although ACS and CCS lesions presented comparable clinical characteristics, including age, sex, and cause of death, the latter exhibited a significantly higher prevalence of chronic kidney disease and hemodialysis than the former (33.3% vs. 65.2%; <em>P</em> = .02, 7.7% vs. 30.4%; <em>P</em> = .02). The poststent implant median duration was significantly shorter in ACS lesions than in CCS lesions (13 [IQR 5-26 days] vs. 40 [IQR 16-233 days]; <em>P</em> &lt; .01). The endothelial coverage percentage was 3.5% at 30 days and 27.7% at 90 days after currently available DES implantation. Multivariable logistic regression analysis implicated implant duration of ≤90 days (odds ratio [OR], 0.009; 95% confidence interval [CI], 0.006-0.012; <em>P</em> &lt; .01), superficial calcification (OR, 0.11; 95% CI, 0.07-0.17; <em>P</em> &lt; .01), ACS culprit site (OR, 0.29; 95% CI, 0.09-0.94; <em>P</em> = .039), and circumferentially durable polymer-coated DES (OR, 0.32; 95% CI, 0.24-0.41; <em>P</em> &lt; .01) as delayed endothelial coverage predictors.</p></div><div><h3>Conclusions</h3><p>Endothelial coverage was limited at 90 days after currently available DES implantation, and the ACS culprit site and circumferentially durable polymer-coated DES were identified as independent predictors of delayed endothelial coverage. Our findings suggest the importance of underlying plaque morphology and stent technology for vessel healing after such implantation.</p></div>\",\"PeriodicalId\":7868,\"journal\":{\"name\":\"American heart journal\",\"volume\":\"277 \",\"pages\":\"Pages 114-124\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0002870324001972/pdfft?md5=a6d96a92c2b7b068b125c59613afe3dc&pid=1-s2.0-S0002870324001972-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American heart journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0002870324001972\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002870324001972","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:在目前可用的药物洗脱支架(DES)植入术后,预防支架血栓形成(ST)的双联抗血小板疗法的最佳持续时间仍存在争议。延迟愈合经常被认为是早期 ST 的主要原因。然而,目前还缺乏对目前可用的 DES 植入术后支架覆盖情况的彻底病理调查--本研究弥补了这一空白:方法:从我们对 199 个支架病变的尸检登记中,对 66 个目前可用的 DES 支架病变中植入时间≤370 天的 4713 个支架进行了组织学评估。内皮覆盖的定义是支架上存在管腔内皮细胞和下层平滑肌细胞层。将支架病变分为急性冠状动脉综合征(ACS)组(n = 40)和慢性冠状动脉综合征(CCS)组(n = 26),并进行比较。通过逻辑分析确定了内皮覆盖的预测因素:虽然 ACS 和 CCS 病变的临床特征(包括年龄、性别和死因)相似,但后者的慢性肾病和血液透析患病率明显高于前者(33.3% 对 65.2%;P = 0.02,7.7% 对 30.4%;P = 0.02)。ACS 病变的支架植入后中位持续时间明显短于 CCS 病变(13 [IQR 5-26 天] vs. 40 [IQR 16-233 天];P < 0.01)。植入目前可用的 DES 后,30 天和 90 天的内皮覆盖率分别为 3.5%和 27.7%。多变量逻辑回归分析显示,植入时间≤90 天[几率比 (OR),0.009;95% 置信区间 (CI),0.006-0.012;P < 0.01]、表层钙化(OR,0.11;95% CI,0.07-0.17;p < 0.01)、ACS罪魁祸首部位(OR,0.29;95% CI,0.09-0.94;p = 0.039)和圆周耐久性聚合物涂层DES(OR,0.32;95% CI,0.24-0.41;p < 0.01)为延迟内皮覆盖预测因子:结论:目前可用的DES植入90天后内皮覆盖有限,ACS罪魁祸首部位和圆周耐久性聚合物涂层DES被确定为延迟内皮覆盖的独立预测因素。我们的研究结果表明,潜在的斑块形态和支架技术对此类植入后的血管愈合非常重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Pathological evaluation of predictors for delayed endothelial coverage after currently available drug-eluting stent implantation in coronary arteries: Impact of lesions with acute and chronic coronary syndromes

Background

The optimal duration of dual antiplatelet therapy after currently available drug-eluting stent (DES) implantation to prevent stent thrombosis (ST) remains controversial. Delayed healing is frequently identified as a leading cause of ST in the early phase. However, a thorough pathological investigation into strut coverage after currently available DES implantation is lacking—a gap addressed in the current study.

Methods

From our autopsy registry of 199 stented lesions, 4,713 struts from 66 currently available DES-stented lesions with an implant duration ≤370 days were histologically evaluated. Endothelial coverage was defined as the presence of luminal endothelial cells overlying struts and an underlying smooth muscle cell layer. The stented lesions were classified into acute coronary syndrome (ACS) (n = 40) and chronic coronary syndrome (CCS) (n = 26) groups and were compared. Endothelial coverage predictors were identified through logistic analysis.

Results

Although ACS and CCS lesions presented comparable clinical characteristics, including age, sex, and cause of death, the latter exhibited a significantly higher prevalence of chronic kidney disease and hemodialysis than the former (33.3% vs. 65.2%; P = .02, 7.7% vs. 30.4%; P = .02). The poststent implant median duration was significantly shorter in ACS lesions than in CCS lesions (13 [IQR 5-26 days] vs. 40 [IQR 16-233 days]; P < .01). The endothelial coverage percentage was 3.5% at 30 days and 27.7% at 90 days after currently available DES implantation. Multivariable logistic regression analysis implicated implant duration of ≤90 days (odds ratio [OR], 0.009; 95% confidence interval [CI], 0.006-0.012; P < .01), superficial calcification (OR, 0.11; 95% CI, 0.07-0.17; P < .01), ACS culprit site (OR, 0.29; 95% CI, 0.09-0.94; P = .039), and circumferentially durable polymer-coated DES (OR, 0.32; 95% CI, 0.24-0.41; P < .01) as delayed endothelial coverage predictors.

Conclusions

Endothelial coverage was limited at 90 days after currently available DES implantation, and the ACS culprit site and circumferentially durable polymer-coated DES were identified as independent predictors of delayed endothelial coverage. Our findings suggest the importance of underlying plaque morphology and stent technology for vessel healing after such implantation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American heart journal
American heart journal 医学-心血管系统
CiteScore
8.20
自引率
2.10%
发文量
214
审稿时长
38 days
期刊介绍: The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.
期刊最新文献
Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS. Chest pain and coronary artery disease in cardiac amyloidosis: Prevalence, mechanisms, and clinical implications. Changes in coverage, access, and health status among adults with cardiovascular disease after medicaid work requirements. Impact of Moderate or Severe Mitral and Tricuspid Valves Regurgitation after Transcatheter Aortic Valve Replacement. Efficacy of Dual Antiplatelet therapy after Ischemic Stroke According to hsCRP Levels and CYP2C19 Genotype.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1